Career history of Sukhi Jagpal
Former positions of Sukhi Jagpal
| Companies | Position | Start | End |
|---|---|---|---|
| SIERRA ONCOLOGY, INC. | Director of Finance/CFO | 2015-01-31 | 2022-06-30 |
QLT, Inc.
 QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Comptroller/Controller/Auditor | 2003-02-28 | 2013-03-05 |
| Director of Finance/CFO | 2012-07-09 | 2015-01-25 |
Training of Sukhi Jagpal
| Queen's University | Masters Business Admin |
| Johnson Graduate School of Management | Masters Business Admin |
Statistics
International
| Canada | 4 |
| United States | 2 |
Operational
| Masters Business Admin | 2 |
| Director of Finance/CFO | 2 |
| Comptroller/Controller/Auditor | 1 |
Sectoral
| Consumer Services | 3 |
| Commercial Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
- Stock Market
- Insiders
- Sukhi Jagpal
- Experience
